pearl index
Recently Published Documents


TOTAL DOCUMENTS

34
(FIVE YEARS 17)

H-INDEX

4
(FIVE YEARS 1)

GYNECOLOGY ◽  
2021 ◽  
Vol 23 (5) ◽  
pp. 380-385
Author(s):  
Vera N. Prilepskaya ◽  
Elena A. Mezhevitinova ◽  
Elena G. Nazarenko ◽  
Elena A. Gorodnova

Background. In recent years, interest in the use of barrier methods of contraception has increased, since many women prefer them in connection with the change in the epidemiological situation associated with COVID-19, with contraindications to other methods of contraception, as well as with irregular sex life and casual sexual intercourse. In addition, these methods of contraception are preferred for breastfeeding mothers and pre- and postmenopausal women. Studies of the efficacy of spermicidal agents in late reproductive age women have not previously been carried out, although their use in this population is of particular interest, since these agents do not have a systemic effect and, if used correctly, can prevent unwanted pregnancies. The article presents data from an international French-Russian study of the efficacy of spermicides containing benzalkonium chloride in late reproductive age women (over 40 years). The study was carried out on the basis of 7 private offices of obstetricians and gynecologists in France and 6 obstetric and gynecological clinics in Russia. Aim. Assessment of the contraceptive efficacy, safety and acceptability of a cream containing benzalkonium chloride in women over 40 years of age. Materials and methods. The study included non-pregnant women aged 40 and over who had at least 1 menstrual period in the past 3 months and who would like to use spermicides as contraception for at least 6 months. After a 6-month period of mandatory use of spermicide, patients could, if desired, continue to use it for the next 6 months. All women were given Pharmatex (1.2%), a vaginal cream containing benzalkonium chloride (1.2 g per 100 g of cream) as the active ingredient, 1 standard dose before each intercourse. The primary endpoint was the Pearl Index. The acceptability of the method after each use of the cream, the moisturizing effect, and the woman's and researcher's overall satisfaction with this method of contraception were also assessed. Safety was assessed using adverse event monitoring. Results. An analysis of efficacy of the study drug showed that during study, pregnancy did not occur in any of the women. Pearl Index for 12 months was 0. Over the mandatory 6-month period, the use of Pharmatex cream was assessed by patients as acceptable (to some extent acceptable, acceptable, completely acceptable) in 98% of sexual intercourse, and over the 12-month period in 98.6% of intercourse. The moisturizing effect of the cream was noted by 96.1% of women. In 6 months of the use of Pharmatex cream, overall satisfaction was rated as quite good, good, or very good by 99.3% of patients and in 12 months by 100% of patients. Adverse events were noted only in 0.5% of cases. Most of these events were assessed as unrelated to the study drug. Conclusion. The use of a benzalkonium chloride spermicidal cream can be considered an effective and acceptable method of contraception for women over the age of 40. It is well tolerated, has a moisturizing effect on the vaginal mucosa, and meets the needs and lifestyle of women. The contraceptive with benzalkonium chloride has a favorable safety profile: it does not adversely affect the normal flora of the vagina, can be used during breastfeeding, since it does not penetrate into the vascular bed and doesnt have systemic effects.


2021 ◽  
Vol 1 (1) ◽  
pp. 001-008
Author(s):  
Nonye-Enyidah Esther Ijeoma ◽  
Lebara L.B ◽  
Enyidah Nonyenim Solomon

Background: Jadelle (Norplant 2) is a levonorgestrel contraceptive implants that is safe, reversible, convenient, very effective and suitable for many women. Although it has numerous benefits, its use is still discontinued due to various reasons including side effects in the body of acceptors. Objective: To determine the prevalence rate, side effects, discontinuation rate and reasons for discontinuation of Jadelle at Rivers State University Teaching Hospital (RSUTH), Port Harcourt, Nigeria. Methods: A retrospective study of 874 clients attending birth control clinic at the RSUTH from 1st January, 2015 – 31st December, 2019 was conducted. Their records were recovered from the clinic and studied. Data was extracted, coded and investigated using the statistical package for social sciences (SPSS) IBM version 25.0 (Armonk, NY). Results: Of 874 acceptors of contraceptives within the study period, one hundred and forty two used Jadelle giving an uptake rate of 16.2%. Jadelle use accounted for third most used contraceptive after implanon and intra uterine contraceptive device (IUCD) during the study period. The mean age was 32.9+4.21 years. Most age group was 30-34 years accounting for 57.8%. Age range was 20-48 years and most (81.7%) were multiparous. Christians accounted for 99.3% and 98.4% were married. All the clients had formal education. Thirty nine (27.5%) acceptors discontinued the use. Most were due to menorrhagia (33.3%) and desire for pregnancy (23.1%). Two unintended pregnancies occurred giving a Pearl index of 0.28 per 100 women-year. Conclusion: Jadelle is safe and effective. Menstrual abnormalities were the commonest side effects complained by the clients. Menstrual abnormalities and desire for pregnancy were the commonest reasons for discontinuation of Jadelle use.


2021 ◽  
Author(s):  
Anita L Nelson

A new low-dose, once-a-week contraceptive transdermal delivery system (TDS) with 2.3-mg ethinyl estradiol (EE) and 2.6-mg levonorgestrel (LNG; Twirla®) has recently been approved by the US FDA for contraception of women with BMI <30 kg/m2. The rationale for developing this new patch, the preclinical study results and the results from two innovative Phase III clinical trials demonstrate that this patch has an acceptable Pearl index (4.3%) for its indicated users and has safety and tolerability comparable to other similar dose oral combined hormonal contraceptives. This new TDS provides an improvement over the existing TDS products, with significantly lower steady-state estrogen exposure, a level equal to that with 30-µg EE containing oral contraceptives.


2020 ◽  
Vol 8 (2) ◽  
pp. 271-278
Author(s):  
Nonye-Enyidah Esther Ijeoma ◽  
Enyidah Nonyenim Solomon

Background: Subdermal contraceptive implants are safe, convenient, very effective and reversible. Though they have numerous benefits, their use is still discontinued due to various reasons including side effects in the body of acceptors. Objective: To determine and compare the prevalence rates, side effects, discontinuation rates and indications for discontinuation of two subdermal implants (Jadelle and Implanon) at Rivers State University Teaching Hospital (RSUTH), Port Harcourt, Nigeria. Methods: A retrospective study of 874 clients attending family planning clinic at the RSUTH from 1st January, 2015 – 31st December, 2019 was conducted. Their records were retrieved from the clinic and reviewed. Data was extracted, coded and analyzed using the statistical package for social sciences (SPSS) IBM version 25.0 (Armonk, NY). Result: Four hundred and twenty five women used subdermal implants out of 874 acceptors of contraceptives within the study period giving an uptake rate of 48.6%. Implanon was more preferred accounting for 66.6% and Jadelle 33.4%. The mean age was 33.24+4.13 years. Most age group was 30-34 years accounting for 51.3%. Age range was 20-48 years and most (80%) were multiparous. Most (99.1%) were Christians and 98.4% were married. Only one client (0.2%) had no formal education. Seventy three (26.4%) acceptors discontinued the use. Most were due to desire for pregnancy (46.4%) and menorrhagia (24.1%). Four unintended pregnancies occurred giving a Pearl index of 0.9. Conclusion: Subdermal implants are safe and effective. Menstrual abnormality and desire for pregnancy were the commonest reasons for discontinuation.


Author(s):  
Kupina A.D. ◽  
Petrov Yu.A. ◽  
Arndt I.G. ◽  
Evdokimova E.P. ◽  
Chernavsky V.V.

Currently, the problem of family planning is not only medical, but also social. The reason for this is the widespread use of artificial termination of pregnancy in our country. Moreover, the majority of women in Russia resort to the extremely dangerous method of abortion - acute curettage, which is associated with a high risk of further infertility and the development of long-term adverse consequences. It is necessary to inform all patients of reproductive age about the neg-ative consequences of artificial termination of preg-nancy and the possibilities of modern methods of con-traception. One of the most popular in our country (in second place after combined oral contraceptives) and highly effective (Pearl index is 0.1-0.5) methods of contraception is the intrauterine device. Intrauterine systems (IUDs) are reversible long-term contraception, which makes them easy to use and affordable. The IUD is installed for 5 years and does not require constant monitoring by the patient. If necessary, the device can be removed at any time. Another positive aspect is that fertility is restored after 12 months in 80-96% of cas-es. Also, intrauterine contraceptives have the thera-peutic effect, since the local action allows you to nor-malize the menstrual cycle, which is especially im-portant for women suffering from hyperpolymenor-rhea and chronic anemia. It has been proven that IUDs do not increase the risk of developing endome-trial and cervical malignant tumors and, in addition, have antiproliferative and antimitotic effects, which makes it possible to use them in patients with complex atypical hyperplasia and highly differentiated stage IA endometrial adenocarcinoma.


2020 ◽  
Author(s):  
Santiago Palacios ◽  
Enrico Colli ◽  
PEDRO ANTONIO REGIDOR

Abstract Background: A new estrogen-free contraceptive has been approved by both the FDA and more than 15 European authorities. It is composed of drospirenone (DRSP) at a dosage of 4 mg in a regimen 24/4. The molecule is known to have anti-gonadotropic, anti-mineralocorticoid, anti-estrogenic, and antiandrogenic properties. The purpose of these clinical trials with a new estrogen-free contraceptive was to introduce a contraceptive method with high efficacy and showing a profile with low cardiovascular risks.Methods: Three European and American multicenter clinical trials have been conducted in more than 2,500 patients and more than 25,000 cycles, not only demonstrating an excellent efficacy (Pearl Index of 0.73) but also investigating possible cardiovascular risks. In the USA study, 422 participants (41.9 %) had a risk factor for VTE, while in the European studies, 261 patients (16.6 %) had at least one VTE risk factor. Amount of arterial and venous thromboembolic events, hemostasiological data, blood pressure development, and ECG data were evaluated. Results: No single case of VTE was documented, no changes in hemastosiological parameters were observed, a small decrease in RR in patients with pretreatment values between 130 and 140 and/or 85 to 90 mm HG and no influence on ECG parameters were observed.Conclusions: The introduction of a new estrogen-free contraceptive with 4 mg of non-micronized drospirenone in a 24/4-day regimen expands contraception options for women as not only a high efficacy could be demonstrated during clinical trials but also a very high cardiovascular safety profile was observed even in women with cardiovascular risk factors.EudraCT registration numbers: 2010-021787-15 & 2011-002396-42. Clincaltrials.gov: NCT02269241


2020 ◽  
Author(s):  
Santiago Palacios ◽  
Enrico Colli ◽  
PEDRO ANTONIO REGIDOR

Abstract Background: A new estrogen-free contraceptive has been approved by both the FDA and more than 15 European authorities. It is composed of drospirenone (DRSP) at a dosage of 4 mg in a regimen 24/4. The molecule is known to have anti-gonadotropic, anti-mineralocorticoid, anti-estrogenic, and antiandrogenic properties. The purpose of these clinical trials with a new estrogen-free contraceptive was to introduce a contraceptive method with high efficacy and showing a profile with low cardiovascular risks.Methods: Three European and American multicenter clinical trials have been conducted in more than 2,500 patients and more than 25,000 cycles, not only demonstrating an excellent efficacy (Pearl Index of 0.73) but also investigating possible cardiovascular risks. In the USA study, 422 participants (41.9 %) had a risk factor for VTE, while in the European studies, 261 patients (16.6 %) had at least one VTE risk factor. Amount of arterial and venous thromboembolic events, hemostasiological data, blood pressure development, and ECG data were evaluated. Results: No single case of VTE was documented, no changes in hemastosiological parameters were observed, a small decrease in RR in patients with pretreatment values between 130 and 140 and/or 85 to 90 mm HG and no influence on ECG parameters were observed.Conclusions: The introduction of a new estrogen-free contraceptive with 4 mg of non-micronized drospirenone in a 24/4-day regimen expands contraception options for women as not only a high efficacy could be demonstrated during clinical trials but also a very high cardiovascular safety profile was observed even in women with cardiovascular risk factors.EudraCT registration numbers: 2010-021787-15 & 2011-002396-42. Clincaltrials.gov: NCT02269241


2020 ◽  
Vol 35 (11) ◽  
pp. 2515-2523
Author(s):  
R Nave ◽  
J Höchel ◽  
U Mellinger ◽  
A Kohnke ◽  
J Elliesen ◽  
...  

Abstract STUDY QUESTION What is the reason for insufficient contraceptive efficacy of levonorgestrel (LNG) delivered by intravaginal ring (IVR) releasing comparable amounts of LNG as approved progestogen-only pills (POPs)? SUMMARY ANSWER The pharmacokinetic (PK) evaluation in a subpopulation indicated that the steady-state concentration of plasma LNG was markedly lower in the participants in the USA compared to those in Japan suggesting non-compliance in the US participants which may explain a clearly higher Pearl Index (PI) in USA (8.2, unadjusted PI) compared to Japan (1.4, unadjusted PI). WHAT IS KNOWN ALREADY Contraceptive efficacy of LNG in POPs has been demonstrated following different routes of administration (e.g. orally, implants, intrauterine systems), and the PK is well-characterized including a target exposure needed for contraception. Exposure above this target concentration was reached in Phase 1 studies using IVR delivering 40 µg LNG per day. STUDY DESIGN, SIZE, DURATION The primary objective of this multicenter, open-label, single-arm study conducted in the USA and in Japan was to assess the contraceptive efficacy of an LNG-containing IVR during a planned treatment period of 1 year in healthy women 18–35 years of age. The study was planned to be conducted in 1600 participants (1300 in the USA, 300 in Japan). The study was prematurely terminated after approximately one-third of the planned exposure was reached due to a high number of pregnancies (28) in the US study population. PARTICIPANTS/MATERIALS, SETTING, METHODS In total, 1471 participants were treated (1166 participants in the USA and 305 participants in Japan). The PI as a measure of contraceptive efficacy was calculated from the frequency of unintended pregnancies during treatment. LNG exposure in the systemic circulation was assessed during treatment in 136 participants (PK subgroups: 106 in the USA and 30 in Japan). MAIN RESULTS AND THE ROLE OF CHANCE The PK evaluation in the PK subgroups indicated that the steady-state concentration of plasma LNG after 6 months was markedly lower in the participants in the USA (geometric mean 91.2 ng/l) compared to those in Japan (263.8 ng/l). This PK finding cannot be explained by the regional differences in body weight observed between the PK subgroups, thus suggesting non-compliance in the US participants. In 15.7% of the samples collected in the USA and 3.5% samples in Japan, the LNG concentration at steady state was below the lower limit of quantification (10 ng/l), which is not expected with the required continuous use of the IVR documented in most of the eDiaries. LIMITATIONS, REASONS FOR CAUTION The planned duration of treatment was 12 months, but due to the premature termination of the study none of the participants completed the 12-month treatment. All data collected until the study termination were considered, but it is to be noted that the amount of missing data limits the conclusions that can be drawn from the data. WIDER IMPLICATIONS OF THE FINDINGS The results of this study triggered the termination of the project, because the objective to show sufficient contraceptive efficacy of the LNG IVR was not met. The choice of a user-dependent contraceptive method with an LNG dose that is not inhibiting ovulation is not advisable for women who may have compliance issues. STUDY FUNDING/COMPETING INTEREST(S) The study was funded by Bayer AG and all authors are employees of Bayer AG. TRIAL REGISTRATION NUMBER NCT02403401


2020 ◽  
Author(s):  
Santiago Palacios ◽  
Enrico Colli ◽  
Pedro Antonio Regidor

Abstract Background: A new estrogen-free contraceptive has been approved by both the FDA and more than 15 European authorities. It is composed of drospirenone at a dosage of 4 mg in a regimen 24/4. The molecule is known to have anti-gonadotropic, anti-mineralocorticoid, anti-estrogenic, and antiandrogenic properties.Methods: The purpose of these clinical trials with a new estrogen-free contraceptive was to introduce a method with high efficacy and showing a profile with low cardiovascular risks.Study design: Three European and American multicenter clinical trials have been conducted in more than 2.500 patients and more than 25.000 cycles, not only demonstrating an excellent efficacy (Pearl Index of 0.73) but also investigating possible cardiovascular risks. In the USA study, 422 participants (41,9 %) had a risk factor for VTE, while in the European studies, 261 patients (16,6 %) had at least one VTE risk factor. Amount of arterial and venous thromboembolic events, hemostasiological data, blood pressure development, and ECG data were evaluated. Results: No single case of VTE was documented, no changes in hemastosiological parameters were observed, a small decrease in RR in patients with pretreatment values between 130 and 140 and7or 85 to 90 mm HG and no influence on ECG parameters were observed.Conclusions: The introduction of a new estrogen-free contraceptive with 4 mg of non-micronized drospirenone in a 24/4-day regimen expands contraception options for women as not only a high efficacy could be demonstrated during clinical trials but also a very high cardiovascular safety profile was observed even in women with cardiovascular risk factors.EudraCT registration numbers: 2010-021787-15 & 2011-002396-42. Clincaltrials.gov: NCT02269241


2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Idriss Ziani ◽  
Imad Boualaoui ◽  
Ahmed Ibrahimi ◽  
Hachem El Sayegh ◽  
Lounis Benslimane ◽  
...  

The intrauterine device (IUD) is one of the most effective contraceptive methods. Its Pearl Index is less than 1 per 100 women. It is the most used method around the world: about 100 million users. However, its insertion can cause certain complications, such as infection, expulsion, or perforation essentially when the rules of use are poorly applied. Perforation remains exceptional but one of the most serious complications. Indeed, after a perforation, the IUD could be located in different neighboring organs. We report a new case of IUD ectopic location in the peritoneal cavity, which was diagnosed 7 years after the insertion and as part of the renal colic assessment. The surgery was performed to remove the IUD which was embedded in the peritoneum and compresses the ureter and causes dilation upstream. To our knowledge, this is the first case reported in the literature of an ectopic location in the retroperitoneal space of an intrauterine device.


Sign in / Sign up

Export Citation Format

Share Document